Cyclacel Pharmaceuticals Inc. is a biotechnology firm based in Dundee, Scotland, and Short Hills, New Jersey, developing cancer drugs and treatments.

Cyclacel Pharmaceuticals, Inc. is a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases.

Sir David Lane, a recognized leader in the field of tumor suppressor biology, who discovered the p53 protein, founded the company in 1996.

Sapacitabine (CYC682), a cell cycle modulating nucleoside analogue, failed its Phase 3 trial for the treatment of acute myeloid leukemia (AML) in the elderly.

[3] Cyclacel completed a reverse merger with Xcyte Therapies in December 2005 to acquire Nasdaq listing.